Trade Names:Colchicine- Tablets 0.6 mgColchicine-Odan (Canada)
Inhibits inflammation and reduces pain and swelling associated with gouty arthritis.
Rapidly absorbed. T max is 0.5 to 2 h.
Large amounts present in bile and intestinal secretions. High concentrations also found in kidney, liver, and spleen. About 50% protein bound. Vd is 1 to 3 L/kg.
Undergoes enterohepatic recirculation. Deacetylated primarily by the liver.
Plasma t ½ to 10 to 60 min. Excreted via biliary and renal routes; 10% to 20% excreted unchanged in urine.
Treatment and relief of pain in attacks of acute gouty arthritis; regular prophylaxis between attacks and is often effective in aborting an attack when taken at the first sign of articular discomfort.
Familial Mediterranean fever; hepatic cirrhosis; primary biliary cirrhosis; treatment of Behcet disease; scleroderma; Sweet syndrome.
Serious GI, renal, hepatic, or cardiac disorders; blood dyscrasias.
Initial dose (give at first sign of attack) PO 1.2 mg; then 0.6 every h or 1.2 mg every 2 h until pain is relieved or diarrhea ensues. Total dose is usually 4 to 8 mg. Wait 3 days before initiating a second course of therapy.ProphylaxisAdults
PO 0.6 mg/day for 3 to 4 days/wk if fewer than 1 attack/yr; if more than 1 attack/yr, 0.6 mg/day. Severe cases may require 1.2 to 1.8 mg/day.Surgical PatientsAdults
PO 0.6 mg 3 times daily for 3 days before and 3 days after surgery.
Store tablets in airtight, light-resistant container.
None well documented.
May cause false-positive results in urine tests for RBCs and hemoglobin.
Dermatoses; purpura; alopecia.
Nausea; vomiting; diarrhea; abdominal pain.
Bone marrow depression with aplastic anemia; agranulocytosis, leukopenia or thrombocytopenia (long-term therapy).
Elevated alkaline phosphatase and AST.
Reversible azoospermia; myopathy; peripheral neuritis.
Check blood counts periodically in patients undergoing long-term therapy.Toxicity signs
Assess for signs of toxicity (eg, abdominal pain, alopecia, nausea, vomiting, diarrhea, myopathy, peripheral neuritis). Notify health care provider immediately if these signs occur.Uric acid/Creatinine
Monitor serum uric acid and creatinine throughout therapy.
Category C (oral).
Safety and efficacy not established.
Administer with great caution to elderly and debilitated patients.
Increased colchicine toxicity may occur.
Drug may cause nausea, vomiting, diarrhea, and abdominal pain that may aggravate pre-existing peptic ulcer or spastic colon. Discontinue drug if these symptoms appear.
Myoneuropathy may occur and cause weakness in patients with impaired kidney function; serum creatine kinase may be elevated. Usually resolves in 3 to 4 wk after drug withdrawal.
Colchicine induces reversible malabsorption of vitamin B 12 with long-term use.
Nausea, severe abdominal pain, vomiting, diarrhea, shock, ST segment elevation, paralysis, respiratory failure, liver damage, renal failure, leukopenia, thrombocytopenia, coagulopathy, alopecia, stomatitis.
Copyright © 2009 Wolters Kluwer Health.